| Literature DB >> 24920253 |
Neelja Singhal1, Manish Kumar2, Jugsharan Singh Virdi1.
Abstract
Beta-lactams are used as major therapeutic agents against a number of infectious agents. Due to widespread use of β-lactams, β-lactamases have evolved at a rapid pace leading to treatment failures. Yersinia enterocolitica causes many gastrointestinal problems. It is an extremely heterogeneous species comprising more than fifty serotypes and six biotypes which differ in their ecological niches, geographical distribution and pathogenic potential. Though biotype 1A strains have been associated with outbreaks of Yersiniosis, there has been a controversy regarding their pathogenicity. The strains of Y. enterocolitica isolated from India belonged to biotype 1A and possessed genes for two β-lactamases namely, blaA and blaB. An earlier study by us reported differential expression of blaA by strains of Y. enterocolitica biotype 1A. The present study has been carried out to understand the molecular bases which regulate the expression of blaA in Y. enterocolitica biotype 1A. We concluded that six types of blaA variants were present in strains of biotype 1A. Neither amino acid substitutions in blaA nor mutations in promoter regions of blaA contributed to differential expression of blaA in Y. enterocolitica biotype 1A. Rather, the secondary structures attained by mRNA of blaA might underlie the differential expression of blaA in Y. enterocolitica.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24920253 PMCID: PMC4053712 DOI: 10.1038/srep05270
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
MIC of selected antibiotics for Y. enterocolitica biotype 1A strains
| Strain no. | Source | Country | Serotype | AMX (mg/L) | AMC (mg/L) | CTX (mg/L) | CPD (mg/L) |
|---|---|---|---|---|---|---|---|
| Clinical | India | O:6,30–6, 31 | >256(R) | >256(R) | 0.64(S) | 1(S) | |
| Clinical | India | O:6,30–6, 31 | >256(R) | >256(R) | 0.125(S) | 2(S) | |
| Clinical | India | O:6,30–6, 31 | >256(R) | 192(R) | 0.036(S) | 0.75(S) | |
| Clinical | India | O:6,30–6, 31 | >256(R) | 128(R) | 0.125(S) | 2(S) | |
| Wastewater | India | O:6,30–6, 31 | >256(R) | 128(R) | 0.19(S) | 2(S) | |
| Wastewater | India | O:6,30–6, 31 | >256(R) | 192(R) | 0.38(S) | 3(I) | |
| Wastewater | India | O:6,30–6, 31 | >256(R) | 64(R) | 0.75(S) | 8(R) | |
| Clinical | India | O:6,30–6, 31 | >256(R) | 128 (R) | 0.19(S) | 8(R) | |
| Clinical | India | O:6, 30 | >256(R) | >256(R) | 0.125(S) | 3(I) | |
| Clinical | India | O:6, 30 | >256(R) | >256(R) | 0.064(S) | 1(S) | |
| Wastewater | India | O:15 | >256(R) | 96(R) | 0.64(S) | 1(S) | |
| Wastewater | India | O:41, 42 | >256(R) | 192(R) | 0.125(S) | 2(S) | |
| Clinical | India | O:41, 43 | >256(R) | >256 (R) | 0.125(S) | 0.3(I) | |
| Pig throat | India | ND | >256(R) | 192(R) | 0.125(S) | 2(S) | |
| Clinical | India | O:6, 30 | >256(R) | 192(R) | 0.25(S) | 4(I) | |
| Clinical | India | O:6, 30 | >256(R) | 64 (R) | 0.094(S) | 2(S) | |
| Clinical | India | O:6, 30 | >256(R) | 128(R) | 0.25(S) | 4(I) | |
| Wastewater | India | O:6, 30–6, 31 | >256(R) | >256(R) | 0.25(S) | 4(I) | |
| Clinical | India | NAG | >256(R) | 192(R) | 0.25(S) | 3(I) | |
| Clinical | India | NAG | >256(R) | 192(R) | 0.25(S) | 3(I) | |
| Clinical | Germany | O:6, 30 | >256(R) | 128(R) | 0.75(S) | 8(R) | |
| Clinical | Germany | O:6, 30 | 64(S) | 0.75(S) | 0.032(S) | 0.125(S) | |
| Clinical | NK | O:6, 30 | >256(R) | 128 (R) | 0.75(S) | 8(R) | |
| Clinical | France | O:6, 30 | >256(R) | 192 (R) | 0.38 (S) | 2(S) | |
| Clinical | France | O:6, 30 | >256(R) | 64(R) | 0.75 (S) | 4(I) |
AMX, amoxicillin; AMC, co-amoxiclav; CTX, cefotaxime CPD, cefpodoxime;
Alphabets in parenthesis indicate antibiotic susceptibility; R-resistant, I-intermediate, S-sensitive.
ND - not determined; NAG - non agglutinable; NK-not known.
Mean specific activities of β-lactamase (blaA) variants of Y.enterocolitica biotype 1A strains
| blaA variant | No. of strains in which the variant was present(n) | Mean specific activity (μmol/min/mg of protein) of β-lactamase |
| blaA1 | 12 | 0.150 ± 0.02 |
| blaA2 | 1 | 0.853 |
| blaA3 | 16 | 0.153 ± 0.04 |
| blaA4 | 4 | 0.030 ± 0.02 |
| blaA5 | 1 | 0.10 |
| blaA6 | 1 | 0.20 |
All values are represented as mean ± standard error of mean (SEM).
Figure 1Multiple sequence alignment of the promoter region of blaA of representative strains of Y.enterocolitica.
The transcription start site ATG, −10 region and −30 regions are shown in bold face; −10 and −30 regions were highly conserved in all the strains.
Amino acid substitutions in the blaA of Y.enterocolitica biotype 1A strains
| Sr. No. | Strain designation | Source | Serotype | Amino acid change |
|---|---|---|---|---|
| 1. | Wastewater (India) | O:6,30–6,31 | P32S | |
| 2. | Human stools (India) * Human (Europe) | O:6,30 | P32S | |
| 3. | Human stools (India) | NAG | P32S | |
| 4. | Human (Europe) | O:6,30 | G58A | |
| 5. | Wastewater (India) | O:41,42 | G58A | |
| 6. | Wastewater (India) | O:6,30–6,31 | G60C | |
| 7. | Human stools (India) *Human (Europe) | O:6,30 | G60C | |
| 8. | Human stools (India) | NAG | G60C | |
| 9. | Wastewater (India) | O:41,42 | R69Q | |
| 10. | Human (Europe) | O:6,30 | R69Q | |
| 11. | Wastewater (India) | O:6,30–6,31 | L98T | |
| 12. | Wastewater (India) | O:6,30–6,31 | N101D | |
| 13. | Human (Europe) | O:6,30 | I113V | |
| 14. | Human (Europe) | O:6,30 | L144V | |
| 15. | Human (Europe) | O:6,30 | T225 S |
Figure 2The blaA variants present in biotype 1A strains of Y.enterocolitica, where n represents the number of strains in which this type of amino acid sequence was observed.
Figure 3Phylogenetic analysis of blaA gene of Y.enterocolitica biotype 1A strains.
Estimated inhibition constants, free energy of binding, H-bond interactions and hydrophobic interactions between amoxicillin and blaA variants of Y. enterocolitica biotype 1A
| blaA variant | Estimated Inhibition Constant, Ki | Free Energy of Binding (kcal/mol) | Interacting Residues | |
|---|---|---|---|---|
| blaA1 | 57.12 uM | −5.79 | 75S, 135S, 137N, 175N, 242S | |
| 78K, 109S, 110Y, 171E, 172P, 221T, 243G, 244D, 279R | ||||
| blaA2 | 14.30 uM | −6.61 | 75S, 78K, 135S, 221T, 242S, 279R | |
| 74C, 109S, 110Y, 137N, 171E, 172P, 175N, 240T, 241G | ||||
| blaA3 | 4.31 uM | −7.32 | 75S, 109S, 135S, 137N, 171, 242, 279 | |
| 78K, 110Y, 134Y, 175N, 221T, 240T | ||||
| blaA4 | 21.79 uM | −6.36 | 135S, 137N, 175N, 240T, 242S | |
| 75S, 78K, 109S, 110Y, 171E, 221T, 241G, 243G | ||||
| blaA5 | 116.57 uM | −5.37 | 75S, 109S, 135S, 137N, 175N, 242S | |
| 78K, 110Y, 171E, 172P, 221T, 243G | ||||
| blaA6 | 15.17 uM | −6.57 | 75S, 135S, 137N, 171H, 242S, 279H | |
| 78K, 110Y, 175N, 221T, 240T | ||||
Estimated inhibition constants, free energy of binding, H-bond interactions and hydrophobic interactions between clavulanic acid and blaA variants of Y. enterocolitica biotype 1A
| blaA variant | Estimated Inhibition Constant, Ki | Free Energy of Binding (kcal/mol) | Interacting Residues | |
|---|---|---|---|---|
| blaA1 | 812.13 uM | −4.22 | 75S, 135S, 242S | |
| 78K, 110Y, 137N, 221T, 239K, 240T, 241G, 249N | ||||
| blaA2 | 649.90 uM | −4.35 | 75S, 78K, 135S | |
| 110Y, 137N, 175N, 240T, 241G, 242S | ||||
| blaA3 | 392.72 uM | −4.65 | 75S, 135S, 221T, 239K, 242S | |
| 78K, 110Y, 134Y, 137N, 240T, 241G | ||||
| blaA4 | 1.11 uM | −4.03 | 75S, 135S, 137N | |
| 74C, 109S, 110Y, 171E, 175N, 242S | ||||
| blaA5 | 159.42 uM | −4.98 | 135S, 240T, 242S, 239K | |
| 75S, 221T, 241G, 248T, 249N, 277P, 279R, 282L | ||||
| blaA6 | 150.09 uM | −5.18 | 135S, 240T, 242S | |
| 75S, 221T, 239K, 241G, 248T, 249N, 277P, 279R, 282L |
Figure 4Molecular docking analysis of the six blaA variants with amoxicillin and clavulanic acid.
Molecular interactions of docked blaA1 (a & b), blaA2 (c & d), blaA3 (e & f), blaA4 (g & h), blaA5 (i & j), blaA5 (k & l) and blaA6 (m & n) with amoxicillin and clavulanic acid respectively. The two antibiotics are represented by stick and the interacting amino acids are shown in dark color.
Figure 5The mRNA secondary structures of blaA1 (a), blaA2 (b), blaA3(c), blaA4 (d), blaA5 (e) and blaA6 (f) predicted by mfold based on complete coding sequences of different blaA variants.